RoyaltyStat

No ORCID on file · 17 papers in corpus · active 2019-2020

Study types

  • article 17

Condition tags

  • endometriosis 17
  • infertility 2
article 2020
Exclusive copyright, patent, know how, process and technology cross-license to exploit, develop, research, manufacture, label, package, process, commercialize, promote, market, sell, distribute, import, export and sublicense the TAK-385 and TAK-448 products and chemical or oligopeptide compounds, to treat, prevent, cure or control symptoms of uterine fibroids, endometriosis or prostate cancer.
·doi:10.34675/l37337
article 2020
Exclusive patent and know-how license to develop, use, sell, offer for sale, have sold, import, export, commercialize and sublicense, with nonexclusive rights to manufacture pharmaceutical products containing the D-63153 compound, which is a LHRH antagonist, as an active ingredient alone or as combination-preparations, for all human uses, including for oncology, such as benign hyperplasia, prostate cancer, and related endometriosis.
·doi:10.34675/l37626
article 2019
Amendment to exclusive patent, know-how and technology license to make, have made, develop, research, improve, use, process, offer, import, sell and distribute therapeutic and prophylactic products related to LHRH antagonist compounds, for uses in the biomedical field, including oncology and reproductive endocrinology treatments, including breast and prostate cancer, endometriosis, uterine fibroid, fertility, polycystic ovarian disease and precocious puberty.
·doi:10.34675/l15368
article 2019
Amendment to exclusive patent, know-how and technology to make, have made, use, sell, offer, export, import, label, package and sublicense products related to LHRH antagonist compounds for all human therapeutic, prophylactic and diagnostic uses, including prostrate cancer and endometriosis indications, but excluding veterinary uses.
·doi:10.34675/l24196
article 2019
Amendment to exclusive patent, know-how and technology to make, have made, use, sell, offer, export, import, label, package and sublicense products related to LHRH antagonist compounds for all human therapeutic, prophylactic and diagnostic uses, including prostrate cancer and endometriosis indications, but excluding veterinary uses.
·doi:10.34675/l21061
article 2019
Amendment to exclusive patent, know-how and technology to make, have made, use, sell, offer, export, import, label, package and sublicense products related to LHRH antagonist compounds for all human therapeutic, prophylactic and diagnostic uses, including prostrate cancer and endometriosis indications, but excluding veterinary uses.
·doi:10.34675/l24195
article 2019
Amendment to exclusive patent license to use licensor's genetic companion diagnostic test for the determination of the existence and predisposition of endometriosis and related conditions as an on-label indication to manufacture, use, sell, offer and administer an endometriosis therapeutic.
·doi:10.34675/l35992
article 2019
Collaboration with exclusive patent, know-how, process and technology license to make, have made, use, sell, import and sublicense products comprising compounds against specific targets, including Chk1 inhibitors having activity with Ki, pKb or EC50 for enzymes and non-enzymatic receptor antagonists or agonists, for the fields of vascular disease, oncology, inflammatory disease, including angiogenesis, ocular conditions, endometriosis, atherosclerosis, cardiac ischemia, congestive heart failure, renal disease, thrombosis, asthma, chronic pulmonary, pulmonary hypertension, and transplant rejection, with exclusive patent, know-how, process and technology license back to licensor in the field, for biotherapeutic, refused or returned candidate products.
·doi:10.34675/l36830
article 2019
Collaborative program with exclusive patent, know-how, process and technology license to make, have made, use, sell, offer, import and sublicense products based on certain compounds against specific targets, including Chk1 inhibitors having activity with a Ki, pKb or EC50 for enzymes and non-enzymatic receptor antagonists or agonists, including those candidate products that were refused or returned by the other party, and compounds that meet the activity threshold against biotherapeutic targets, for the fields of vascular biology-based disease, oncology and inflammatory disease, including inflammatory and malignant angiogenesis, ocular conditions, underlying malignant and pre-dysplastic, endometriosis, atherosclerosis, cardiac ischemia, congestive heart failure, renal disease, thrombosis, asthma, chronic obstructive pulmonary, pulmonary hypertension, and transplant rejection.
·doi:10.34675/l36835
article 2019
Exclusive patent and know-how license and sublicense to develop, use, import, offer, advertise, promote, distribute, sell and sublicense therapeutic products which contain Lutenizing Hormone Releasing Hormone (LHRH) antagonist compounds, for any therapeutic uses, including treatment of prostate cancer, breast cancer, endometriosis, uterine fibroids, benign prostatic hypertrophy, infertility, and precocious puberty.
·doi:10.34675/l24557
article 2019
Exclusive patent, know-how and technology license to develop, make, have made, use, have used, register, promote, market, distribute, sell, and have sold any product comprising an anti-GnRH or an antiGnRH receptor immunogen construct for use in the diagnosis, treatment and prevention of gonadotropin, gonadal steroid hormones or GnRH receptors associated diseases and cancers in humans including endometriosis, polycystic ovaries, uterine fibroids, contraception, infertility, precocious puberty, prostate cancer, breast cancer, ovarian cancer and endometrial cancer.
·doi:10.34675/l15457
article 2019
Exclusive patent, know-how and technology license to make, have made, develop, research, improve, use, process, offer, import, sell, distribute and sublicense therapeutic and prophylactic products related to LHRH antagonist compounds, for uses in the biomedical field, including oncology and reproductive endocrinology treatments, including breast and prostate cancer, endometriosis, uterine fibroid, fertility, polycystic ovarian disease and precocious puberty.
·doi:10.34675/l15227
article 2019
Exclusive patent, know-how, and trademark license to use, market, promote, distribute and sell all dosage strengths and forms of the 'Histrelin Hydron Implant' containing histrelin acetate and sold in a kit with materials and accessories, for the treatment of prostate cancer, central precocious puberty (CPP) and other indications that may be developed, other than endometriosis.
·doi:10.34675/l9960
article 2019
Exclusive patent license to make, have made, sublicense, use, import, sell, distribute and offer for sale products and provide services in the diagnostic applications or uses involving dysfunctions or diseases of the female reproductive system, such as endometriosis.
·doi:10.34675/l15330
article 2019
Sale of all interest in assets including contracts, drug application registrations, the 'Plenaxis' trademarks and trade names, patents, know-how, technical information, promotional and marketing materials, customer and supplier lists, marketing studies, product inventory and materials, manufacturing equipment, product records, government authorizations and shares, with royalty on the sale of products containing abarelix in any formulation, including the 'Plenaxis' product formulated in 'Rel-Ease' or similar formulation to treat prostate cancer, abarelix products for injectable suspension, an abarelix product to treat endometriosis including sustained release or depot formulations, and other products under sublicense.
·doi:10.34675/l35322
article 2019
Sale of all interest in assets including contracts, drug application registrations, the 'Plenaxis' trademarks and trade names, patents, know-how, technical information, promotional and marketing materials, customer and supplier lists, marketing studies, product inventory and materials, manufacturing equipment, product records, government authorizations and shares, with royalty on the sale of products containing abarelix in any formulation, including the 'Plenaxis' product formulated in 'Rel-Ease' or similar formulation to treat prostate cancer, abarelix products for injectable suspension, an abarelix product to treat endometriosis including sustained release or depot formulations, and other products under sublicense.
·doi:10.34675/l35396
article 2019
Sale of all interest in assets including contracts, drug application registrations, the 'Plenaxis' trademarks and trade names, patents, know-how, technical information, promotional and marketing materials, customer and supplier lists, marketing studies, product inventory and materials, manufacturing equipment, product records, government authorizations and shares, with royalty on the sale of products containing abarelix in any formulation, including the 'Plenaxis' product formulated in 'Rel-Ease' or similar formulation to treat prostate cancer, abarelix products for injectable suspension, an abarelix product to treat endometriosis including sustained release or depot formulations, and other products under sublicense.
·doi:10.34675/l35397